retatrutide mechanism gip glp-1 glucagon triple agonist of action GLP-1-based therapies for type Retatrutide: The triple agonist powering
Description
Drug-Metabolizing Enzyme- and Transporter- Mediated DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA To date, no clinically relevant drug-metabolizing enzyme- or transporter-mediated DDIs involving GLP-1 RAs or a dual GLP-1/GIP RA have been reported (Table 3)
There was an observed U-shape association between serum DPP-4 and mortality in patients with chronic systolic HF, and Loureno et al
These hormones are secreted from intestinal mucosal cells, and GLP-1 can be detected in the circulation minutes after oral ingestion of nutrients
34 : S65S72
Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM
